HUP0204418A2 - Nhe-1 inhibitor n-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives and use thereof - Google Patents
Nhe-1 inhibitor n-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives and use thereofInfo
- Publication number
- HUP0204418A2 HUP0204418A2 HU0204418A HUP0204418A HUP0204418A2 HU P0204418 A2 HUP0204418 A2 HU P0204418A2 HU 0204418 A HU0204418 A HU 0204418A HU P0204418 A HUP0204418 A HU P0204418A HU P0204418 A2 HUP0204418 A2 HU P0204418A2
- Authority
- HU
- Hungary
- Prior art keywords
- membered
- substituted
- unsaturated
- alkyl
- compounds
- Prior art date
Links
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title 1
- 150000002357 guanidines Chemical class 0.000 title 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical group [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
A találmány tárgya (I) általános képletű vegyületek, előgyógyszereikvagy a vegyületek vagy előgyógyszereik gyógyászatilag elfogadható sói,a képletben Z jelentése szénatomon keresztül kapcsolódó 5-tagú, kétszomszédos nitrogénatomot tartalmazó kétszeresen telítetlen gyűrű,amely adott esetben az R1, R2 és R3 helyettesítők közül egymástólfüggetlenül választott legfeljebb három csoporttal helyettesített;vagy Z jelentése szénatomon keresztül kapcsolódó 5-tagú, háromnitrogénatomot és két telítetlen kötést tartalmazó gyűrű, amely adottesetben egymástól függetlenül az R4 és R5 helyettesítők közülválasztott legfeljebb két helyettesítővel helyettesített; ahol R1, R2,R3, R4 és R5 jelentése egymástól függetlenül hidrogénatom, hidroxi-alkil-, alkil-, alkil-tio-, cikloalkil-, cikloalkil-alkil-, alkoxi-,alkoxi-alkil-, mono-N- vagy di-N,N-karbamoil-, M vagy M-alkil-csoport,ahol a fenti alkilmolekula részek adott esetben 1-9 fluoratomottartalmaznak; továbbá az alkil- vagy cikloalkilcsoportok adott esetbenegymástól függetlenül helyettesítettek; ahol M jelentése részlegesentelített, teljesen telített vagy teljesen telítetlen 5-8 tagúheterogyűrű, vagy két kondenzált részlegesen telített, teljesentelített vagy teljesen telítetlen 3-6-tagú gyűrűből álló biciklusosheterogyűrű; továbbá M adott esetben legfeljebb három csoporttalhelyettesített. A találmány tárgyát képezi továbbá a fenti vegyületekalkalmazása nátrium-hidrogén csere 1 típusú (NHE-1) gátló hatásúgyógyászati készítmények előállítására, amelyek előnyösen isémiakezelésére alkalmasak. ÓThe subject of the invention is compounds of the general formula (I), their prodrugs or pharmaceutically acceptable salts of the compounds or their prodrugs, in the formula Z is a 5-membered doubly unsaturated ring containing two neighboring nitrogen atoms connected through a carbon atom, which is optionally chosen independently from among the substituents R1, R2 and R3 substituted by up to three groups; or Z is a 5-membered ring connected through a carbon atom, containing three nitrogen atoms and two unsaturated bonds, optionally substituted by up to two substituents selected from the R4 and R5 substituents; where R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, hydroxyalkyl, alkyl, alkylthio, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, mono-N or di -N,N-carbamoyl, M or M-alkyl group, where the above alkyl molecular parts optionally contain 1-9 fluorine atoms; moreover, the alkyl or cycloalkyl groups are optionally substituted independently of each other; where M is a partially unsaturated, fully saturated or fully unsaturated 5-8 membered heteroring, or a bicyclic heteroring consisting of two fused partially saturated, fully saturated or fully unsaturated 3-6 membered rings; moreover, M may be substituted by up to three groups. The subject of the invention is also the use of the above compounds for the production of medicinal preparations with an inhibitory effect on sodium hydrogen exchange type 1 (NHE-1), which are advantageously suitable for the treatment of ischemia. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7636298P | 1998-02-27 | 1998-02-27 | |
| PCT/IB1999/000206 WO1999043663A1 (en) | 1998-02-27 | 1999-02-05 | N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0204418A2 true HUP0204418A2 (en) | 2003-04-28 |
| HUP0204418A3 HUP0204418A3 (en) | 2003-10-28 |
Family
ID=22131525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0204418A HUP0204418A3 (en) | 1998-02-27 | 1999-02-05 | Nhe-1 inhibitor n-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives and use thereof |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6492401B1 (en) |
| EP (2) | EP1056729B1 (en) |
| JP (2) | JP2002504546A (en) |
| KR (4) | KR100407903B1 (en) |
| CN (1) | CN1289326A (en) |
| AP (1) | AP9901478A0 (en) |
| AR (1) | AR015526A1 (en) |
| AT (1) | ATE286034T1 (en) |
| AU (1) | AU739403B2 (en) |
| BG (1) | BG104803A (en) |
| BR (1) | BR9908332A (en) |
| CA (1) | CA2321642A1 (en) |
| CO (1) | CO4980897A1 (en) |
| DE (1) | DE69922930T2 (en) |
| DK (1) | DK1056729T3 (en) |
| DZ (1) | DZ2729A1 (en) |
| EA (1) | EA003603B1 (en) |
| ES (1) | ES2237080T3 (en) |
| GT (1) | GT199900022A (en) |
| HR (2) | HRP20000550A2 (en) |
| HU (1) | HUP0204418A3 (en) |
| ID (1) | ID25505A (en) |
| IL (1) | IL136588A0 (en) |
| IS (1) | IS5548A (en) |
| NO (1) | NO20004192L (en) |
| NZ (1) | NZ504769A (en) |
| OA (1) | OA11450A (en) |
| PA (1) | PA8468401A1 (en) |
| PE (1) | PE20000334A1 (en) |
| PL (1) | PL342444A1 (en) |
| PT (1) | PT1056729E (en) |
| SI (1) | SI1056729T1 (en) |
| SK (1) | SK12342000A3 (en) |
| TN (1) | TNSN99028A1 (en) |
| TR (1) | TR200002480T2 (en) |
| TW (1) | TWI226329B (en) |
| WO (1) | WO1999043663A1 (en) |
| YU (1) | YU46200A (en) |
| ZA (1) | ZA991578B (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136588A0 (en) * | 1998-02-27 | 2001-06-14 | Pfizer Prod Inc | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia |
| FR2795726A1 (en) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | NEW FUNGICIDE PYRAZOLES |
| UA72002C2 (en) * | 1999-10-29 | 2005-01-17 | Pfizer Prod Inc | Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage |
| US6441176B1 (en) | 1999-10-29 | 2002-08-27 | Pfizer Inc. | Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| YU54202A (en) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation |
| HN2001000008A (en) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| WO2001079198A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
| US6852733B2 (en) * | 2000-04-28 | 2005-02-08 | Pfizer Inc. | Sodium-hydrogen exchanger type 1 inhibitor |
| AU2001235896A1 (en) * | 2000-04-28 | 2001-11-12 | Pfizer Products Inc. | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| JP2004514706A (en) | 2000-11-28 | 2004-05-20 | ファイザー・プロダクツ・インク | Preparation of sodium-hydrogen exchanger type 1 inhibitors |
| IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| CN1479737A (en) * | 2001-01-31 | 2004-03-03 | �Ʒ� | Ethanolates of sodium-proton exchanger protein type-1 inhibitor |
| WO2002098429A1 (en) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat |
| AU2002352148A1 (en) * | 2001-06-29 | 2003-03-03 | Abbott Gmnh & Co. Kg | Bis-aryl thiazole derivatives |
| MXPA04003124A (en) * | 2001-11-02 | 2004-11-29 | Aventis Pharma Inc | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor. |
| JP2005511787A (en) | 2001-12-19 | 2005-04-28 | ファイザー・プロダクツ・インク | Method for preparing sodium-hydrogen exchange type 1 inhibitor |
| CA2472342A1 (en) * | 2002-01-30 | 2003-08-07 | Pfizer Products Inc. | Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide |
| CA2483927A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| FR2840302B1 (en) * | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | ISOINDOLONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIARY THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME |
| FR2842525B1 (en) * | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| FR2842526B1 (en) * | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS COMPRISING A 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVE, PROCESS FOR THE PREPARATION AS MEDICAMENTS |
| FR2842524B1 (en) * | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE DERIVATIVE, PROCESS FOR PREPARING THE SAME AS MEDICAMENTS |
| EP1590338B1 (en) * | 2002-12-04 | 2009-08-26 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
| CN100436445C (en) * | 2003-02-07 | 2008-11-26 | 第一制药株式会社 | Pyrazole derivative |
| WO2005047297A1 (en) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| WO2005079803A1 (en) * | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
| US7786163B2 (en) | 2004-07-12 | 2010-08-31 | Forest Laboratories Holdings Limited (BM) | Constrained cyano compounds |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006055462A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| EP1853296B1 (en) * | 2005-01-10 | 2012-06-20 | Debiopharm S.A. | Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| EP2046753A2 (en) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CN101687873A (en) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 11 beta-hydroxysteroid dehydrogenase type i inhibitors with annelated heterocycles |
| JP2010534722A (en) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | Novel glucokinase activator and method of use thereof |
| WO2009134754A1 (en) | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazole glycinamides as prolyl hydroxylase inhibitors |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| EP2386546B1 (en) * | 2008-11-21 | 2015-08-19 | RaQualia Pharma Inc | Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity |
| WO2010094090A2 (en) * | 2009-02-18 | 2010-08-26 | Katholleke Universiteit Leuven | Synucleinopathies |
| US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| CN102408385B (en) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | Preparation method of 2-substituent-2H-1,2,3-triazole derivative |
| CN102408386B (en) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | Preparation method of 2,4-disubstituted-2H-1, 2, 3-triazole derivatives |
| JP2014527973A (en) | 2011-09-23 | 2014-10-23 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | Use of 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress |
| BR112014009910B1 (en) | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | 1- (5,6-dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt, pharmaceutical composition and topical ointment |
| EP2819675A4 (en) * | 2012-02-27 | 2015-07-22 | Essentialis Inc | Salts of potassium atp channel openers and uses thereof |
| KR20180032576A (en) | 2015-08-06 | 2018-03-30 | 우베 고산 가부시키가이샤 | Substituted guanidine derivatives |
| WO2017057695A1 (en) * | 2015-09-30 | 2017-04-06 | 東レ株式会社 | Diphenylpyrazol derivative and use thereof for medical purposes |
| PT3395801T (en) * | 2015-12-16 | 2021-05-24 | Nippon Soda Co | Arylazole compound and pest control agent |
| WO2018058109A1 (en) | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| CN108017584B (en) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3Small molecule antagonists of adenosine receptors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2104931B1 (en) * | 1970-09-08 | 1975-01-10 | Ferlux | |
| CA2121391A1 (en) * | 1993-04-28 | 1994-10-29 | Atsuyuki Kojima | Indoloylguanidine derivatives |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| EP0639573A1 (en) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| DE4412334A1 (en) * | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituted N-heteroaroylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
| CA2160600A1 (en) * | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Indoloylguanidine derivatives |
| CA2195697A1 (en) | 1996-02-02 | 1997-08-03 | Masahumi Kitano | Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof |
| JPH09291076A (en) | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | Substituted guanidine derivative and its production |
| ZA9711102B (en) * | 1996-12-16 | 1998-08-13 | Yamanouchi Pharma Co Ltd | N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative |
| IL136588A0 (en) * | 1998-02-27 | 2001-06-14 | Pfizer Prod Inc | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia |
-
1999
- 1999-02-05 IL IL13658899A patent/IL136588A0/en unknown
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/en not_active Application Discontinuation
- 1999-02-05 DK DK99901083T patent/DK1056729T3/en active
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/en not_active IP Right Cessation
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/en not_active Application Discontinuation
- 1999-02-05 YU YU46200A patent/YU46200A/en unknown
- 1999-02-05 ES ES99901083T patent/ES2237080T3/en not_active Expired - Lifetime
- 1999-02-05 EP EP99901083A patent/EP1056729B1/en not_active Expired - Lifetime
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Application Discontinuation
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/en not_active IP Right Cessation
- 1999-02-05 DE DE69922930T patent/DE69922930T2/en not_active Expired - Fee Related
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/en unknown
- 1999-02-05 EP EP04008203A patent/EP1454902A1/en not_active Withdrawn
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/en active Pending
- 1999-02-05 ID IDW20001633A patent/ID25505A/en unknown
- 1999-02-05 AT AT99901083T patent/ATE286034T1/en not_active IP Right Cessation
- 1999-02-05 CN CN99802628A patent/CN1289326A/en active Pending
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/en not_active Application Discontinuation
- 1999-02-05 EA EA200000789A patent/EA003603B1/en not_active IP Right Cessation
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/en not_active IP Right Cessation
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/en unknown
- 1999-02-05 SI SI9930743T patent/SI1056729T1/en unknown
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 PL PL99342444A patent/PL342444A1/en not_active Application Discontinuation
- 1999-02-05 PT PT99901083T patent/PT1056729E/en unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/en active
- 1999-02-22 GT GT199900022A patent/GT199900022A/en unknown
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/en not_active Application Discontinuation
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/en unknown
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/en unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/en active
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/en unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/en unknown
-
2000
- 2000-06-27 IS IS5548A patent/IS5548A/en unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192L/en not_active Application Discontinuation
- 2000-08-24 HR HR20000550A patent/HRP20000550A2/en not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/en unknown
-
2001
- 2001-08-29 HR HR20010666A patent/HRP20010666A2/en not_active Application Discontinuation
-
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0204418A2 (en) | Nhe-1 inhibitor n-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives and use thereof | |
| DK1140916T3 (en) | Heteroaryl cyclic acetals | |
| HUP0301120A2 (en) | Substituted phenylamino-quinazolin derivatives, their use for the treatment of abnormal cell growth and pharmaceutical compositions containing them | |
| HUP9802822A2 (en) | Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients | |
| HUP0300743A2 (en) | Heteroaryl derivatives and use thereof as medicaments | |
| NO306237B1 (en) | Use of xanthine derivatives as antidepressants | |
| PT1159279E (en) | 4-OXO-4,7-DIHYDROTIENE-2,3-B | PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | |
| CA2206005A1 (en) | Aniline derivatives possessing an inhibitory effect of nitric oxide synthase | |
| DE69505968T2 (en) | AZOLIDINDION DERIVATIVES AND THEIR USE AS ANTI-HYPERGLYCEMAS | |
| GEP20084284B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| TW368501B (en) | 7-(2-aminoethyl)-benzothiazolones | |
| BR0010324A (en) | Compound, pharmaceutical composition, and method of preparing a compound | |
| ES2105617T3 (en) | PIPERACINE DERIVATIVES AS 5-HT ANTAGONISTS. | |
| NZ330078A (en) | Active oxygen carriers containing pterin derivatives and salts thereof for use as cosmetic agents and feed | |
| IL102367A (en) | Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists, processes for preparing them and pharmaceutical compositions containing them | |
| TW360652B (en) | Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them | |
| HUP9901387A2 (en) | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| YU30603A (en) | Bridged piperazine derivatives | |
| TW429255B (en) | Pyrazine compounds having treatment of central nervous system diseases and disorders | |
| HUP0301587A2 (en) | 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect, pharmaceutical compositions containing them and processes for their preparations | |
| HUP0000321A2 (en) | Aromatic amine derivatives having nos inhibitory effect, process for producing them and pharmaceutical compositions containing them | |
| IL108258A0 (en) | Piperazine derivates, their preparation and pharmaceutical compositions containing them | |
| HUP9702393A2 (en) | Bis(2-haloethyl)aminophenyl substituted distamycin derivatives as antitumor and antiviral agents | |
| HUP0105407A2 (en) | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates | |
| TW333532B (en) | Benzopyrans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC4A | Lapse of provisional application due to refusal |